natgillin/translations-raw huggingface dataset:
If treatment is discontinued: Patients who show evidence of acute liver injury while on Tasmar and are withdrawn from the medicinal product may be at increased risk for liver injury if Tasmar is reintroduced. 
Ako se prekida liječenje: bolesnici koji pokazuju znakove akutnog oštećenja jetre dok su na Tasmaru i koji prestanu uzimati taj lijek mogu imati povećani rizik od oštećenja jetre kod ponovnog uvođenja Tasmara.
This may include: o 
To može uključivati:
The treatment will be stopped, if these blood tests become abnormal. 
Ako ovi krvni nalazi budu abnormalni, liječenje će biti prekinuto.
Tell your doctor or a pharmacist as soon as possible: if you do not feel well while you are taking Tasmar if you experience symptoms such as nausea, vomiting, abdominal pain, loss of appetite, weakness, fever, darkening of urine or jaundice since uncommonly disturbances in the way the liver works, sometimes severe hepatitis was observed, if you notice a darkening of your urine since this could be a sign of a muscular or liver injury. 
Obavijestite svog liječnika ili ljekarnika što je prije moguće: - ako se ne osjećate dobro dok uzimate Tasmar - ako imate simptome kao što su mučnina, povraćanje, bol u trbuhu, gubitak apetita, slabost, vrućica, tamnija mokraća ili žutica jer su manje često opaženi poremećaji u načinu rada jetre, a ponekad i teški hepatitis, - ako primijetite da Vam je mokraća tamnija jer to može bit znak mišićnog ili jetrenog oštećenja.
Marketing Authorisation Holder: Meda AB 
Nositelj odobrenja za stavljanje gotovoga lijeka u promet Meda AB
The consequent increase in dopaminergic stimulation can lead to the dopaminergic side effects observed after treatment with COMT inhibitors. 
Posljedično povećanje dopaminergičke stimulacije može dovesti do dopaminergičkih nuspojava opaženih nakon liječenja COMT inhibitorima.
A natural protein (enzyme) in your body, the (COMT) Catechol-O-methyltransferase in your body breaks down levodopa. 
Prirodni protein (enzim) u Vašem tijelu, katehol-O-metiltransferaza (engl. catechol-Omethyltransferase, (COMT) razgrađuje levodopu u Vašem tijelu.
Because of the risk of rare but potentially fatal acute liver injury, Tasmar is only indicated for use in patients with levodopa-responsive idiopathic Parkinson's disease and motor fluctuations, who failed to respond to or are intolerant of other COMT inhibitors. 
Oštećenje jetre: zbog rizika od rijetkog, ali potencijalno smrtonosnog, akutnog oštećenja jetre, Tasmar je indiciran samo za primjenu u bolesnika s idiopatskom Parkinsonovom bolešću koja odgovara na levodopu i motoričkim fluktuacijama, a koji nisu odgovarali ili su intolerantni na druge COMT inhibitore.
Since clinical information is limited regarding the combination of warfarin and tolcapone, coagulation parameters should be monitored when these drugs are co-administered. 
Budući da su klinički podaci koji se odnose na kombinaciju varfarina i tolkapona ograničeni, parametri koagulacije se moraju nadzirati kada se ovi lijekovi primjenjuju istodobno.
If benefits are not seen within 3 weeks of the initiation of the treatment, Tasmar should be discontinued. 
Ako se unutar 3 tjedna od početka liječenja ne vide koristi, liječenje Tasmarom treba prekinuti.
Patients with severe renal impairment (creatinine clearance <30 ml/min) should be treated with caution. 
Bolesnike s teškim oštećenjem bubrega (klirens kreatinina <30 ml/min) treba liječiti s oprezom.
If the dose is increased to 200 mg tid, liver enzyme monitoring should take place before increasing the dose and then be reinitiated following the same sequence of frequencies as above (see sections 4.4 and 4.8). 
Ako se doza poveća na 200 mg tri puta dnevno, prije povećanja doze treba nadzirati jetrene enzime, a zatim ponovno nadzirati prema jednakom slijedu učestalosti koji je naveden gore (vidjeti dijelove 4.4 i 4.8).
The most common of these are increased dyskinesia, nausea, vomiting, abdominal pain, syncope, orthostatic complains, constipation, sleep disorders, somnolence, hallucination. 
Najčešće od njih su pojačana diskinezija, mučnina, povraćanje, bol u abdomenu, sinkopa, ortostatske smetnje, konstipacija, poremećaji spavanja, somnolencija, halucinacije.
Outer Carton and bottle label, 30, 60, 100, 200 film-coated tablets 
Kartonska kutija i naljepnica na bočici, 30, 60, 100, 200 filmom obloženih tableta
A natural protein (enzyme) in your body, the (COMT) Catechol-O-methyltransferase breaks down the levodopa. 
Prirodni protein (enzim) u Vašem tijelu, katehol-O-metiltransferaza (engl. catechol-Omethyltransferase, (COMT) razgrađuje levodopu.
Liver function should be checked before starting treatment with Tasmar and then monitored every 2 weeks for the first year of therapy, every 4 weeks for the next 6 months and every 8 weeks thereafter. 
Prije liječenja Tasmarom treba provjeriti jetrenu funkciju, a zatim je nadzirati svaka 2 tjedna tijekom prve godine terapije, svaka 4 tjedna tijekom sljedećih 6 mjeseci i svakih 8 tjedana nakon toga.
Plasma levels of 3OMD were markedly and dose-dependently decreased by tolcapone when given with levodopa/AADC-I (aromatic amino acid decarboxylase - inhibitor) (benserazide or carbidopa). 
Tolkapon je značajno i ovisno o dozi smanjio plazmatske razine 3-OMD-a kada se davao s levodopom/AADC-I (inhibitor dekarboksilaze aromatske aminokiseline) (benzerazid ili karbidopa).
Česká republika MEDA Pharma s.r.o. 
Slovenská republika MEDA Pharma spol. s. r.o.
While receiving treatment: 
Tijekom liječenja:
Outer Carton and blister packs, 30 and 60 film-coated tablets 
Vanjska kutija i blister pakiranja, 30 i 60 filmom obloženih tableta
Diarrhoea led to withdrawal of 5% and 6% of patients receiving Tasmar 100 mg tid and 200 mg tid respectively, compared to 1 % of patients receiving placebo. 
Proljev je doveo do odustajanja kod 5 % i 6 % bolesnika koji su primali Tasmar 100 mg tri puta dnevno, odnosno 200 mg tri puta dnevno, u usporedbi s 1 % bolesnika koji su primali placebo.
C/Plom, 2-4, 5ª planta 08038 - Barcelona Tel: +34 900 102 712 
Mylan Pharmaceuticals S.L. C/Plom, 2-4, 5ª planta 08038 - Barcelona Tel: +34 900 102 712
Mylan Healthcare B.V Krijgsman 20 
Mylan Healthcare B.V
To improve efficacy your doctor should only increase the dose to 3 times daily 2 tablets (200 mg three times a day) if the increase in how your Parkinson´s disease symptoms are controlled outweighs the expected increase in side effects.The side effects at the higher dose can often be severe and affect your liver. 
Kako bi poboljšao učinkovitost Vaš liječnik smije dozu povećati samo na 3 puta dnevno po 2 tablete (200 mg tri puta dnevno), ako poboljšanje u kontroliranju simptoma Parkinsonove bolesti nadjačava očekivano pojačanje nuspojava.
Rare (≥1/10,000 to < 1/1,000) 
Rijetko (≥1/10 000 i < 1/1000)
If the dose is increased to 200 mg tid, liver enzyme monitoring should take place before increasing the dose and then be re-initiated following the sequence of frequencies as above. 
Ako se doza poveća na 200 mg tri puta dnevno, prije povećanja doze treba nadzirati jetrene enzime, a zatim ponovno nadzirati prema jednakom slijedu učestalosti koji je naveden gore.
30 film-coated tablets 60 film-coated tablets 
30 filmom obloženih tableta 60 filmom obloženih tableta
It is available in blisters in pack sizes of 30 and 60 tablets and in glass bottles in pack sizes of 100 tablets. 
Dostupne su u blisterima u veličinama pakiranja od 30 i 60 tableta te u staklenim bočicama u veličinama pakiranja od 100 tableta.
In the therapeutic range, tolcapone pharmacokinetics are linear and independent of levodopa/AADC-I (benserazide or carbidopa) coadministration. 
U terapijskom rasponu, farmakokinetika tolkapona je linearna i neovisna o istodobnoj primjeni levodope/AADC-I (benzerazid ili karbidopa).
Tasmar is available in PVC/PE/PVDC blisters (pack sizes of 30 and 60 film-coated tablets) and in amber glass bottles without desiccant (pack sizes of 100 film-coated tablets). 
Tasmar je dostupan u PVC/PE/PVDC blisterima (veličine pakiranja od 30 i 60 filmom obloženih tableta) i u staklenim bočicama boje jantara bez sredstva za sušenje (veličine pakiranja od 100 filmom obloženih tableta).
severe symptoms of muscle stiffening, fever or mental confusion (Neuroleptic Malignant Syndrome) when antiparkinsonian treatments are abruptly reduced or withdrawn. 
Rijetko: - teški simptomi ukočenosti mišića, vrućica ili mentalna smetenost (neuroleptički maligni sindrom) kada se liječenje lijekovima za Parkinsonovu bolest naglo smanji ili ukine
It is available in blisters in pack sizes of 30 and 60 tablets and in glass bottles in pack sizes of 30, 60 ,100 and 200 filmcoated tablets. 
Dostupne su u blisterima u veličinama pakiranja od 30 i 60 tableta te u staklenim bočicama u veličinama pakiranja od 30, 60, 100 i 200 filmom obloženih tableta.
may affect more than 1 in 10 people 
mogu se javiti u više od 1 na 10 osoba
Pale to light yellow, hexagonal, biconvex, film-coated tablet. 
Blijeda do svijetložuta, heksagonalna, bikonveksna, filmom obložena tableta.
Warfarin: Since clinical information is limited regarding the combination of warfarin and tolcapone, coagulation parameters should be monitored when these drugs are co-administered. 
Varfarin: budući da je kliničko iskustvo s kombinacijom varfarina i tolkapona ograničeno, trebalo bi nadzirati parametre koagulacije kada se ovi lijekovi primjenjuju istodobno.
Tasmar is indicated in combination with levodopa/benserazide or levodopa/carbidopa for use in patients with levodopa-responsive idiopathic Parkinson's disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-o-methyltransferase (COMT) inhibitors (see section 5.1). 
Tasmar je indiciran u kombinaciji s levodopom/benzerazidom ili levodopom/karbidopom za primjenu u bolesnika s idiopatskom Parkinsonovom bolešću koja odgovara na levodopu i motoričkim fluktuacijama, a koji nisu odgovarali ili su intolerantni na druge inhibitore katehol-O-metiltransferaze (COMT, engl. catechol-O-methyltransferase) (vidjeti dio 5.1).
EU/1/97/044/006 100 tablets 
EU/1/97/044/006 100 tableta
Rare cases of severe hepatocellular injury resulting in death have been reported during marketed use (see section 4.4). 
Tijekom tržišne primjene prijavljeni su rijetki slučajevi hepatocelularnog oštećenja sa smrtnim ishodom (vidjeti dio 4.4).
How to store Tasmar 
Kako čuvati Tasmar
Hepatocellular injury, in rare cases with fatal outcome* (see section 4.4) 
Poremećaji jetre i žuči manje često hepatocelularno oštećenje, u rijetkim slučajevima s fatalnim ishodom (vidjeti dio 4.4)
Skin and subcutaneous tissue disorders 
Poremećaji kože i potkožnog tkiva često pojačano znojenje
EU/1/97/044/007 30 tablets EU/1/97/044/008 60 tablets EU/1/97/044/003 100 tablets EU/1/97/044/0010 200 tablets 
EU/1/97/044/007 30 tableta EU/1/97/044/008 60 tableta EU/1/97/044/003 100 tableta EU/1/97/044/0010 200 tableta
Tasmar is available in PVC/PE/PVDC blisters (pack sizes of 30 and 60 film-coated tablets) and in amber glass bottles without desiccant (pack sizes of 30, 60,100 and 200 film-coated tablets). 
Tasmar je dostupan u PVC/PE/PVDC blisterima (veličine pakiranja od 30 i 60 filmom obloženih tableta) i u staklenim bočicama boje jantara bez sredstva za sušenje (veličine pakiranja od 30, 60, 100 i 200 filmom obloženih tableta).
The following suggestions are based on pharmacological considerations and have not been evaluated in clinical trials. 
Prilagodbe levodope pri ukidanju Tasmara: sljedeće sugestije temelje se na farmakološkim razmatranjima te nisu vrednovane u kliničkim ispitivanjima.
Common (≥1/100 to < 1/10) 
Često (≥1/100 i < 1/10)
Impulse control disorders: Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments such as Tasmar in association with Levedopa (see section 4.4 `special warnings and precautions for use´). 
Poremećaji kontrole impulsa: u bolesnika liječenih agonistima dopamina i/ili drugim dopaminergičkim liječenjima kao što je Tasmar u kombinaciji s levodopom može se javiti patološko kockanje, pojačani libido, hiperseksualnost, kompulzivno trošenje ili kupovanje, prejedanje i kompulzivno jedenje (vidjeti dio 4.4 `posebna upozorenja i mjere opreza pri uporabi´).
However, Tasmar, as a COMT inhibitor, is known to increase the bioavailability of the co-administered levodopa. 
Međutim, poznato je da Tasmar, kao COMT inhibitor, povećava bioraspoloživost istodobno primijenjene levodope.
Tasmar is supplied as film-coated tablets containing 100 mg tolcapone. 
Tasmar se isporučuje kao filmom obložene tablete koje sadrže 100 mg tolkapona.
System organ class 
Klasifikacija organskih sustava Incidencija
Tasmar is supplied as film-coated tablets containing 200 mg tolcapone. 
Tasmar se isporučuje kao filmom obložene tablete koje sadrži 200 mg tolkapona.
Tasmar, as a COMT inhibitor, is known to increase the bioavailability of the co-adminstered levodopa. 
Poznato je da Tasmar, kao COMT inhibitor, povećava bioraspoloživost istodobno primijenjene levodope.
A previous history of Neuroleptic Malignant Syndrome (NMS) Symptom Complex and /or non-traumatic Rhabdomyolysis or Hyperthermia. 
• Anamneza grupe simptoma neuroleptičnog malignog sindroma (NMS) i /ili netraumatske rabdomiolize ili hipertermije.
Excipients with known effect: Each tablet contains 7.5 mg lactose For the full list of excipients, see section 6.1. 
Pomoćne tvari s poznatim učinkom: svaka tableta sadrži 7,5 mg laktoze
may affect up to 1 in 1,000 people 
mogu se javiti u do 1 na 1000 osoba
Transient elevation above pretreatment levels of erythrocyte COMT activity was observed after withdrawal of tolcapone. 
Nakon prekida liječenja tolkaponom opažena su prolazna povišenja aktivnosti eritrocitnog COMT-a viša od razina prije liječenja.
Also contains lactose See leaflet for further information. 
Vidjeti Uputu o lijeku za dodatne informacije.
Dose and frequency of administration 
Doza i učestalost primjene
Postepu 21 B 02-676 Warszawa Tel: +48 22 5466400 
Mylan Healthcare Sp.z.o.o. ul. Postepu 21 B 02-676 Warszawa Tel: +48 22 5466400
Tolcapone does not accumulate with three times daily dosing of 100 or 200 mg. At these doses, Cmax is approximately 3 and 6 µg/ml, respectively. 
Tolkapon se ne akumulira s dozama od 100 do 200 mg tri puta dnevno.
100 film-coated tablets 
100 filmom obloženih tableta.
Slovenská republika MEDA Pharma spol. 
Slovenská republika MEDA Pharma spol. s r.o.
Tablet core: Calcium hydrogen phosphate, Microcrystalline cellulose, Povidone K30, Sodium starch glycollate, Lactose, Talc, Magnesium stearate. 
- Drugi sastojci su: Jezgra tablete: kalcijev hidrogenfosfat, mikrokristalična celuloza, povidon K30, natrijev škroboglikolat, laktoza, talk, magnezijev stearat.
Meda Pharma S.p.A. 
MEDA Pharmaceuticals A.E.
In Parkinson`s patients, NMS tends to occur when discontinuing or stopping dopaminergic-enhancing medications. 
Neuroleptični maligni sindrom (NMS): u bolesnika s Parkinsonovom bolešću, NMS se obično javlja pri prekidu ili prestanku uzimanja lijekova koji povećavaju dopaminergičku aktivnost.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer carton for blister packs [ 30 and 60 film-coated tablets] 
Kartonska kutija za blister pakiranje [ 30 i 60 filmom obloženih tableta]
Very common: involuntary movement (dyskinesia), nausea, decreased appetite, diarrhoea, headache, dizziness sleep problems, somnolence, feeling lightheaded while you stand, (orthostatic complaints),mental confusion and hallucinations, movement disorder with involuntary muscle spasms or malpositions (dystonia), dreaming excessive. 
Vrlo često: - nevoljni pokreti (diskinezija), - mučnina, gubitak apetita, proljev, - glavobolja, omaglica - poremećaji spavanja, izrazita pospanost, - osjećaj ošamućenosti dok stojite (ortostatske smetnje), mentalna smetenost i halucinacije - poremećaj pokreta s nevoljnim mišićnim grčevima ili iskrivljenim položajima (distonija) - prekomjerno sanjanje
Common: chest pain, constipation, dyspepsia, stomach ache, vomiting, dry mouth, fainting increased sweating, influenza-like symptoms reduced voluntary and involuntary movement (hypokinesia) upper respiratory tract infection increase of specific liver enzymes, urine discoloration 
Često: - bol u prsnom košu, - zatvor, probavne tegobe, želučana bol, povraćanje, suha usta - nesvjestica - pojačano znojenje, - simptomi nalik gripi - smanjenje voljnih i nevoljnih pokreta (hipokinezija) - infekcija gornjih dišnih puteva - povećanje specifičnih enzima jetre - promjena boje urina
Upper respiratory tract infection 
Infekcije i infestacije često infekcija gornjeg respiratornog trakta
may affect up to 1 in 100 people 
mogu se javiti u do 1 na 100 osoba
For the treatment of Parkinson´s disease, Tasmar is used together with the medicinal product levodopa (as levodopa/benserazide or levodopa/carbidopa). 
Tasmar se koristi zajedno s levodopom (kao levodopa/benzerazid ili levodopa/karbidopa) za liječenje Parkinsonove bolesti.
As Tasmar decreases the breakdown of levodopa in the body, side effects due to increased levodopa concentrations may occur when beginning Tasmar treatment. 
Prilagodbe levodope tijekom liječenja Tasmarom: budući da Tasmar smanjuje razgradnju levodope u tijelu, pri početku liječenja Tasmarom mogu se javiti nuspojave zbog povišenih koncentracija levodope.
Binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than needed to satisfy your hunger). 
o snažan impuls za prekomjernim kockanjem unatoč ozbiljnim osobnim ili obiteljskim posljedicama o promijenjen ili povećan spolni interes i ponašanje koje značajno zabrinjava vas ili druge, na primjer, pojačani spolni nagon o nekontrolirano prekomjerno kupovanje ili trošenje o prejedanje (jedenje velikih količina hrane u kratkom vremenskom razdoblju) ili kompulzivno jedenje (jedenje više hrane nego što je normalno i više nego što je potrebno za zadovoljenje gladi).
Uncommon (≥1/1,000 to < 1/100) 
Manje često (≥1/1000 i < 1/100)
may affect up to 1 in 10,000 people 
mogu se javiti u do 1 na 10 000 osoba
EU/1/97/044/004 30 tablets EU/1/97/044/005 60 tablets 
EU/1/97/044/004 30 tableta EU/1/97/044/005 60 tableta
What Tasmar looks like and contents of the pack Tasmar is an orange yellow to brown yellow, oval shaped, film-coated tablet. 
Tasmar je narančasto žuta do smeđe žuta, ovalna filmom obložena tableta.
Renal and urinary disorders Common 
Poremećaji bubrega i mokraćnog sustava često diskoloracija urina
EU/1/97/044/001 30 tablets EU/1/97/044/002 60 tablets 
EU/1/97/044/001 30 tableta EU/1/97/044/002 60 tableta
If you get any side effects talk to you doctor or pharmacist. 
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika.
Metabolism and nutrition disorders 
Poremećaji metabolizma i prehrane vrlo često anoreksija
What you need to know before you take Tasmar Do not take Tasmar: if you have liver disease or increased liver enzymes if you have severe involuntary movement (dyskinesia) if you have a previous history of severe symptoms of muscle stiffening, fever or mental confusion (Neuroleptic Malignant Syndrome (NMS) Symptom Complex ) and /or if you have damage of skeletal muscle tissue (non-traumatic Rhabdomyolysis) or fever (Hyperthermia). 
Nemojte uzimati Tasmar: - ako imate bolest jetre ili povišene jetrene enzime - ako imate teške nevoljne pokrete (diskineziju) - ako u povijesti bolesti imate teške simptome kočenja mišića, vrućice ili mentalne smetenosti
Each film-coated tablet contains 200 mg tolcapone tolcapone 200 mg 
Svaka filmom obložena tableta sadrži 200 mg tolkapona 200 mg tolkapona
The active substance is tolcapone (100 mg in each film- coated tablet) The other ingredients are: 
Što Tasmar sadrži - Djelatna tvar je tolkapon (100 mg u svakoj filmom obloženoj tableti)
When beginning and during treatment with Tasmar, your dose of Levodopa may need to be changed. 
Vaša doza levodope će se možda morati promijeniti pri početku i tijekom liječenja Tasmarom.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer carton and bottle label, 100 film-coated tablets 
Kartonska kutija i naljepnica na bočici, 100 filmom obloženih tableta
Impulse control disorders* (Libido increased, hypersexuality, pathological gambling, compulsive spending or buying, binge eating, compulsive eating (see section 4.4)) 
Psihijatrijski poremećaji vrlo često poremećaj spavanja prekomjerno sanjanje somnolencija konfuzija halucinacije rijetko poremećaj kontrole impulsa (povećanje libida, hiperseksualnost, patološko kockanje, kompulzivno trošenje ili kupovanje, prejedanje, kompulzivno jedenje (vidjeti dio 4.4))
Hepatic impairment: Because of the risk of liver injury observed during post-marketing use, Tasmar is contraindicated in patients with liver disease or increased liver enzymes. 
Oštećenje jetre: Tasmar je kontraindiciran u bolesnika s bolešću jetre ili povišenim jetrenim enzimima zbog rizika od oštećenja jetre opaženog tijekom postmarketinške primjene.
may affect up to 1 in 10 people 
mogu se javiti u do 1 na 10 osoba
Tasmar 200 mg film coated tablets 
Tasmar 200 mg filmom obložene tablete
Each film-coated tablet contains 100 mg tolcapone. 
Svaka filmom obložena tableta sadrži 100 mg tolkapona.
Each film-coated tablet contains 200 mg tolcapone. 
Svaka filmom obložena tableta sadrži 200 mg tolkapona.
Excipients with known effect: Each tablet contains 15 mg lactose For the full list of excipients, see section 6.1. 
Pomoćne tvari s poznatim učinkom: svaka tableta sadrži 15 mg laktoze
Calcium hydrogen phosphate Microcrystalline cellulose Povidone K30 
Jezgra tablete: kalcijev hidrogenfosfat celuloza, mikrokristalična povidon K30 natrijev škroboglikolat laktoza talk magnezijev stearat.
NMS (Neuroleptic Malignant Syndrome): Symptoms of Neuroleptic Malignant Syndrome (NMS) may occur during Tasmar treatment. 
Tijekom liječenja Tasmarom mogu se javiti simptomi neuroleptičkog malignog sindroma (NMS).
Each film-coated tablet contains 100 mg tolcapone 
Svaka filmom obložena tableta sadrži 100 mg tolkapona
Dyskinesia Dystonia Headache Dizziness 
Štetni događaji bol u abdomenu dispepsija
What Tasmar contains The active substance is tolcapone (200 mg in each film- coated tablet) The other ingredients are: Tablet core: Calcium hydrogen phosphate, Microcrystalline cellulose, Povidone K30, Sodium starch glycollate, Lactose monohydrate, Talc, Magnesium stearate. 
- Drugi sastojci su: Jezgra tablete: kalcijev hidrogenfosfat, mikrokristalična celuloza, povidon K30, natrijev škroboglikolat, laktoza monohidrat, talk, magnezijev stearat.
Tasmar 100 mg film-coated tablets 
Tasmar 100 mg filmom obložene tablete
What Tasmar looks like and contents of the pack Tasmar is a pale to light yellow, oval shaped, film-coated tablet. 
Tasmar je blijeda do svijetložuta, ovalna filmom obložena tableta.
Vomiting Constipation Xerostomia Abdominal pain Dyspepsia 
Štetni događaji kserostomija bol u abdomenu dispepsija
Neuroleptic Malignant Syndrome Symptom Complex Isolated cases of patients with symptoms suggestive of Neuroleptic Malignant Syndrome Symptom Complex (see sectiom 4.4) have been reported following reduction or discontinuation of Tasmar and following introduction of Tasmar when this was accompanied by a significant reduction in other concomitant dopaminergic medications. 
Nakon smanjenja doze ili prestanka liječenja Tasmarom, ili nakon početka liječenja Tasmarom kada je to bilo praćeno značajnim smanjenjem drugih istodobno primjenjivanih dopaminergičkih lijekova, prijavljeni su izolirani slučajevi bolesnika sa simptomima koji upućuju na grupu simptoma neuroleptičkog malignog sindroma (vidjeti dio 4.4).
Titanium dioxide 
• Teška diskinezija
Dyskinesia 
OBLIK
Neuroleptic Malignant Syndrome Symptom Complex (see section 4.4) 
Poremećaji živčanog sustava vrlo često diskinezija distonija glavobolja omaglica somnolencija ortostatske smetnje rijetko grupa simptoma neuroleptičkog malignog sindroma (vidjeti dio 4.4)
How to store Tasmar Keep this medicine out of the sight and reach of children. 
Ovaj lijek čuvajte izvan pogleda i dohvata djece.
Yellow iron oxide Ethylcellulose 
Film ovojnica: hidroksipropilmetilceluloza talk željezov oksid, žuti etilceluloza titanijev dioksid triacetin natrijev laurilsulfat